| Dr Elaine P Christie, OD | |
|
255 Highview Ln, Media, PA 19063-1146 | |
| (610) 565-7702 | |
| Not Available |
| Full Name | Dr Elaine P Christie |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 255 Highview Ln, Media, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275585986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OET008952 (Pennsylvania) | Primary |
| Provider Name | Peter N Christie |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205805413 PECOS PAC ID: 7315005279 Enrollment ID: I20081021000586 |
News Archive
After four decades on the decline, rheumatoid arthritis is on the upswing among women in the United States. That's the finding presented by Mayo Clinic investigators at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals in San Francisco.
With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.
The student-led Ophthalmology Interest Group recently held a suturing workshop, offering Feinberg students the opportunity to practice surgical techniques on mock organs.
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
An antimicrobial protein caused a dramatic reduction in the creamy white lesions associated with oral thrush in a preclinical study, report microbiologists with McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elaine P Christie, OD 255 Highview Ln, Media, PA 19063-1146 Ph: (610) 565-7702 | Dr Elaine P Christie, OD 255 Highview Ln, Media, PA 19063-1146 Ph: (610) 565-7702 |
News Archive
After four decades on the decline, rheumatoid arthritis is on the upswing among women in the United States. That's the finding presented by Mayo Clinic investigators at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals in San Francisco.
With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.
The student-led Ophthalmology Interest Group recently held a suturing workshop, offering Feinberg students the opportunity to practice surgical techniques on mock organs.
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
An antimicrobial protein caused a dramatic reduction in the creamy white lesions associated with oral thrush in a preclinical study, report microbiologists with McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 9 days ago
Ines M Casado Strine, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 319 W State St, Media, PA 19063 Phone: 610-566-1227 Fax: 610-566-6888 | |
Dr. Judith R Venuto, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 18 S Olive St, Media, PA 19063 Phone: 610-566-2070 | |
Drs E L And R H Kane Pc Optometrist Medicare: Medicare Enrolled Practice Location: 24 E Second St, Media, PA 19063 Phone: 610-566-1693 Fax: 610-566-2229 | |
Mrs. Tricia Louise Korenkiewicz, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1067 W Baltimore Pke, Sears Optical, Media, PA 19063 Phone: 610-565-3416 Fax: 610-566-6815 | |
Mr. Peter M. Palmieri, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1067 West Baltimore Pike, Lenscrafters Dr Patrick Weber And Assoc, Media, PA 19063 Phone: 610-566-7026 Fax: 610-891-9897 | |
Dr. Geoffrey Paterson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 811 Parkridge Dr, Media, PA 19063 Phone: 610-566-7026 |